Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer

Endocrine-Related Cancer

Volumn 12, Issue 4, 2005, Pages 721-747

  Normanno, Nicola ^a   Di Maio, Massimo ^a   De Maio, Ermelinda ^a   De Luca, Antonella ^a   De Matteis, Andrea ^a   Giordano, Antonio ^b   Perrone, Francesco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Temple University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERLOTINIB; ESTROGEN; ESTROGEN RECEPTOR ALPHA; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GEFITINIB; GROWTH FACTOR; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEGESTROL ACETATE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PAROXETINE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TOREMIFENE; TRASTUZUMAB;

ARTHRALGIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RESISTANCE; CARDIOVASCULAR DISEASE; CELL SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; ENDOMETRIUM CANCER; FRACTURE; GYNECOLOGIC DISEASE; HEART DISEASE; HORMONAL REGULATION; HOT FLUSH; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAXIMUM PERMISSIBLE DOSE; METASTASIS; NONHUMAN; OSTEOPOROSIS; PHARMACOGENOMICS; PHENOTYPE; POSTMENOPAUSE; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SIGNAL TRANSDUCTION; STROKE; THROMBOEMBOLISM; TOXICITY; TRANSCRIPTION INITIATION; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINA DISEASE; VAGINAL DRYNESS;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 29144526402     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00857     Document Type: Review

References (170)

1. Argiris A, Wang CX, Whalen SG & DiGiovanna MP 2004 Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clinical Cancer Research 10 1409-1420.
2. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK & Elledge RM 2004 HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group Study. Clinical Cancer Research 10 5670-5676.
3. Arteaga CL, O'Neil A, Moulder SL, Pins M, Sparano JA, Sledge GW & Davidson NE 2004 ECOG1100: a phase I-II study of combined blockade of the erbB receptor network with trastuzmab and gefitinib ('Iressa') in patients (pts) with HER2-overexpressing metastatic breast cancer. Breast Cancer Research and Treatment 88 S1 S15-16 (abstract 25).
4. Atlas E, Cardillo M, Mehmi I, Zahedkargaran H, Tang C & Lupu R 2003 Heregulin is sufficient for the promotion of tumorigenecity and metastasis of breast cancer in vivo. Molecular Cancer Resarch 1 165-175.
5. Bardou VJ, Arpino G, Elledge RM, Osborne CK & Clark GM 2003 Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. Journal of Clinical Oncology 21 1973-1979.
6. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG & Sahmoud T; ATAC Trialists' Group 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 2131-2139.
7. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM & Osborne CK 1993 Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Research and Treatment 24 85-95.
8. Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman DR, Henderson IC, Barcos M, Hayes D & Norton L 2000 HER-2 and p53 expression vs. tamoxifen resistance in estrogen-receptor-positive node-positive breast cancer. Journal of Clinical Oncology 18 3471-3479.
9. Berstein LM, Wang JP, Zheng H, Yue W, Conaway M & Santen RJ 2004 Long-term exposure to tamoxifen induces hypersensitivity to estradiol. Clinical Cancer Research 10 1530-1534.
10. BIG 1-98 Collaborative Group 2005 Letrozole versus tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. BIG 1-98: a prospective randomized double-blind phase III study. Proceedings of the 9th International Conference, Primary Therapy of Early Breast Cancer, St Gallen, Switzerland. Abstract S4.
11. Blackwell KL, Kaplan EH, Franco SX, Marcom PK, Maleski JE, Sorensen MJ & Berger MS 2004 A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. Proceedings of the American Society of Clinical Oncology 23 196 (abstract 3006).
12. Boccardo F, Rubagotti A & Amoroso D, on behalf of the Italian Tamoxifen Arimidex (ITA) trial 2003 Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Research and Treatment 82 S6.
13. Bonneterre J, Thurlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M & von Euler M 2000 Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. Journal of Clinical Oncology 18 3748-3757.
14. Britten CD, Pegram M, Rosen P, Finn RS, Wax A, Bosserman L, Gordon L, Lin LS, Mass R & Slamon DJ 2004 Targeting ErbB receptor interactions: A phase I trial of trastuzumab and erlotinib in metastatic HER2+ breast cancer. Proceedings of the American Society of Clinical Oncology 23 206 (abstract 3045).
15. Britton D, Hutcheson IR, Barrow D, McClelland RA & Nicholson RI 2003 Estrogen receptor phosphorylation in hormone sensitive and anti-hormone resistant breast cancer cells. Breast Cancer Research and Treatment 82 S61.
16. Brodie A, Jelovac D, Macedo L, Sabnis G, Tilghman S & Goloubeva O 2005 Therapeutic observations in MCF-7 aromatase xenografts. Clinical Cancer Research 11 884-888S.
17. Bunone G, Briand PA, Miksicek RJ & Picard D 1996 Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO Journal 15 2174-2183.
18. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A & Lee D 1998 Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 83 1142-1152.
19. Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, Porter L, Nabholtz J, Xiang X & Brady C 2001 Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. Journal of Clinical Oncology 19 3357-3366.
20. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S & Nakshatri H 2001 Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. Journal of Biological Chemistry 276 9817-9824.
21. Cappelletti V, Celio L, Bajetta E, Allevi A, Longarini R, Miodini P, Villa R, Fabbri A, Mariani L, Giovanazzi R, Galante E, Greco M & Daidone MG 2004 Prospective evaluation of estrogen receptor-beta in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients. Endocrine-Related Cancer 11 761-770.
22. Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N & Slingerland JM 2000 Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. PNAS 97 9042-9046.
23. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR & De Placido S 1996 c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. Journal of Clinical Oncology 14 2702-2708.
24. Chan CM, Martin LA, Johnston SR, Ali S & Dowsett M 2002 Molecular changes associated with the acquisition of estrogen hypersensitivity in MCF-7 breast cancer cells on long-term estrogen deprivation. Journal of Steroid Biochemistry and Molecular Biology 81 333-341.
25. Chen JD & Evans RM 1995 A transcriptional co-repressor that interacts with nuclear hormone receptors Nature 377 454-457.
26. Cheung KL, Robertson JF & Scott N 2002 Endocrine response after prior treatment with fulvestrant ('Faslodex') in postmenopausal women with advanced breast cancer. European Journal of Cancer 38 S98.
27. Chung YL, Sheu ML, Yang SC, Lin CH & Yen SH 2002 Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. International Journal of Cancer 97 306-312.
28. Clarke R, Brunner N, Katz D, Glanz P, Dickson RB, Lippman ME & Kern FG 1989 The effects of a constitutive expression of transforming growth factor-alpha on the growth of MCF-7 human breast cancer cells in vitro and in vivo. Molecular Endocrinology 3 372-380.
29. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O et al. 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine 350 1081-1092.
30. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB & Lee AV 2003 Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Molecular Endocrinology 17 575-588.
31. Davis T, Kennedy C, Chiew YE, Clarke CL & deFazio A 2000 Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clinical Cancer Research 6 4334-4342.
32. De Placido S, De Laurentiis M, Carlomagno C, Gallo C, Perrone F, Pepe S, Ruggiero A, Marinelli A, Pagliarulo C, Panico L et al. 2003 Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clinical Cancer Research 9 1039-1046.
33. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M et al. 1998 Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. Journal of Clinical Oncology 16 453-461.
34. Dowsett M 2003 Analysis of time to recurrence in the ATAC (Arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Research and Treatment 82 S7.
35. Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N & Smith I 2001 HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Research 61 8452-8458.
36. Early Breast Cancer Trialist Group 1998 Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 1461-1467.
37. El-Ashry D, Miller DL, Kharbanda S, Lippman ME & Kern FG 1997 Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene 15 423-435.
38. Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S & Osborne CK 1998 HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clinical Cancer Research 4 7-12.
39. Ellis CA, Vos MD, Wickline M, Riley C, Vallecorsa T, Telford WG, Zujewskil J, Clark GJ 2003 Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines. Breast Cancer Research and Treatment 78 59-67.
40. Ellis M 2004 Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist 9 20-26.
41. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E & Borgs M 2001 Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. Journal of Clinical Oncology 19 3808-3816.
42. Fallowfield L, Cella D, Cuzick J, Francis S, Locker G & Howell A 2004 Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. Journal of Clinical Oncology 22 4261-4271.
43. Fan M, Bigsby RM & Nephew KP 2003 The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182780 in ERalpha-positive breast cancer cells. Molecular Endocrinology 17 356-365.
44. Font de Mora J & Brown M 2000 AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Molecular and Cellular Biology 20 5041-5047.
45. Frasor J, Danes JM, Komm B, Chang KCN, Lyttle R & Katzenellenbogen BS 2003 Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144 4562-4574.
46. Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P & Allred DC 2000 A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Research 60 4026-4029.
47. Gee JM, Robertson JF, Ellis IO & Nicholson RI 2001 Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. International Journal of Cancer 95 247-254.
48. Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE & Nicholson RI 2003 The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144 5105-5117.
49. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI et al. 2003 A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New England Journal of Medicine 349 1793-1802.
50. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione MM, Tu D, Shepherd LE & Pater JL 2004 Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer Proceedings of the American Society of Clinical Oncology 23 (abstract 847).
51. Gottardis MM & Jordan VC 1988 Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Research 48 5183-5187.
52. Gottardis MM, Jiang SY, Jeng MH, Jordan VC 1989 Inhibition of tarnoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Research 49 4090-4093.
53. Gradishar WJ 2004 Tamoxifen - What next? Oncologist 9 378-384.
54. Gronemeyer H 1991 Transcription activation by estrogen and progesterone receptors. Annual Review of Genetics 25 89-123.
55. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK & Dowsett M 2005 Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. Journal of Clinical Oncology 23 2469-2476.
56. Hall JM & McDonnell DP 1999 The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140 5566-5578.
57. Herynk MH & Fuqua SA 2004 Estrogen receptor mutations in human disease. Endocrine Reviews 25 869-898.
58. Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Soderstrom M, Glass CK et al. 1995 Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377 397-404.
59. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD & Miles DW 1999 Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. British Journal of Cancer 79 1220-1226.
60. Howell A, DeFriend DJ, Robertson JF, Blamey RW, Anderson L, Anderson E, Sutcliffe FA & Walton P 1996 Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. British Journal of Cancer 74 300-308.
61. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A & Morris C 2002 Fulvestrant, formerly ICI 182780, is as effective anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. Journal of Clinical Oncology 20 3396-3403.
62. Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I & Osborne CK 2004 Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. Journal of Clinical Oncology 22 1605-1613.
63. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY & Tobias JS; ATAC Trialists' Group 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 60-62.
64. Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE & Nicholson RI 2003 Estrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Research and Treatment 81 81-93.
65. Hutcheson IR, Knowlden JM, Barrow D & Nicholson RI 2004 IGF-1R/EGFR crosstalk in tamoxifen resistant MCF-7 breast cancer cells. Proceedings of the American Association for Cancer Research 45 5189.
66. Ingle JN, Rowland KM, Suman VJ, Mirchandani D, Bernath AM, Camoriano JK & Perez EA 2004 Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: a phase II trial of the North Central Cancer Treatment Group. Breast Cancer Research and Treatment 88 S38.
67. Jakesz R, Kaufmann M, Gnant M, Jonat W, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W & Samonigg H 2004 Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial and the ARNO 95 Trial. Breast Cancer Research and Treatment 88 S7.
68. Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J & Lannigan DA 1998 pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Molecular and Cellular Biolology 18 1978-1984.
69. Johnston SR 2005 Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clinical Cancer Research 11 889-899s.
70. Johnston SR & Dowsett M 2003 Aromatase inhibitors for breast cancer: lessons from the laboratory. Nature Reviews Cancer 3 821-831.
71. Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR & Dowsett M 1995 Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Research 55 3331-3338.
72. Johnston SRD, Head JE, Valenti MR, Detre S, Brunton LA, De Rienzo A, Howes AJ, End D, Kaye S & Dowsett M 2002 Endocrine therapy combined with the farnesyl transferase inhibitor (FTI) R115777 produces enhanced tumor growth inhibition in hormone-sensitive MCF-7 human breast cancer xenografts in vivo. Breast Cancer Research and Treatment 76 A245.
73. Jordan NJ, Gee JM, Barrow D, Wakeling AE & Nicholson RI 2004 Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Research and Treatment 87 167-180.
74. Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R & Grohe C 2000 Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. Journal of Biological Chemistry 275 18447-18453.
75. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D & Chambon P 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270 1491-1494.
76. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL & Massimini G 2000 Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. Journal of Clinical Oncology 18 1399-1411.
77. Knoop AS, Bentzen SM, Nielsen MM, Rasmussen BB & Rose C 2001 Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. Journal of Clinical Oncology 19 3376-3384.
78. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE & Nicholson RI 2003a Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144 1032-1044.
79. Knowlden JM, Hutcheson IR, Barrow D & Nicholson RI 2003b IGF-1R and EGFR crosstalk in tamoxifen resistant breast cancer cells. Breast Cancer Research and Treatment 82 S171.
80. Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT & Arteaga CL 2000 Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Research 60 5887-5894.
81. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM & Webb P 2000 Estrogen receptor pathways to AP-1. Journal of Steroid Biochemistry and Molecular Biology 14 311-317.
82. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG & Rose DW 1998 Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. PNAS 95 2920-2925.
83. Leo C & Chen JD 2000 The SRC family of nuclear receptor coactivators. Gene 245 1-11.
84. Levin ER 2003 Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Molecular Endocrinology 17 309-317.
85. Lipton A, Ali SM, Leitzel K, Demers L, Harvey HA, Chaudri-Ross HA, Brady C, Wyld P & Carney W 2003 Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. Journal of Clinical Oncology 21 1967-1972.
86. Liu Y, El-Ashry D, Chen D, Ding IY & Kern FG 1995 MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen dependence and tamoxifen-sensitivity in vivo. Breast Cancer Research and Treatment 34 97-117.
87. Long BJ, Jelovac D, Thiantanawat A & Brodie AM 2002 The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clinical Cancer Research 8 2378-2388.
88. Long BJ, Jelovac D, Handratta V, Thiantanawat A, MacPherson N, Ragaz J, Goloubeva OG & Brodie AM 2004a Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. Journal of the National Cancer Institute 96 456-465.
89. Long BJ, Liu G, Marrinan CH, Maxwell E, Black S, Gheyas F, Nomeir A, Liu M, Kirschmeier P & Bishop WR 2004b Combining the farnesyl transferase inhibitor (FTI) Lonafarnib (SCH66336) with antiestrogens and aromatase inhibitors results in enhanced growth inhibition of hormone-dependent human breast cancer cells and tumor xenografts. Proceedings of the American Association for Cancer Research 45 A3868.
90. Lonning PE 2004 Aromatase inhibitors in breast cancer. Endocrine-Related Cancer 11 179-189.
91. Macaluso M, Cinti C, Russo G, Russo A & Giordano A 2003 pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer. Oncogene 22 3511-3517.
92. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, Gee JM & Nicholson RI 2001 Enhanced epidermal growth factor receptor signaling in MCF-7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182 780 (Faslodex). Endocrinology 142 2776-2788.
93. McDonnell DP 2005 The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer. Clinical Cancer Research 11 871-877s.
94. McDonnel DP, Clemm DL, Hermann T, Goldman ME & Pike JW 1995 Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Molecular Endocrinology 9 659-669.
95. McKenna NJ, Lanz RB & O'Malley BW 1999 Nuclear receptor coregulators: cellular and molecular biology. Endocrine Reviews 20 321-344.
96. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C & Dowsett M 2003 Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. Journal of Biological Chemistry 278 30458-30468.
97. Martin MB, Garcia-Morales P, Stoica A, Solomon HB, Pierce M, Katz D, Zhang S, Danielsen M & Saceda M 1995 Effects of 12-O-tetradecanoilphorbol- 13-acetate on estrogen receptor activity in MCF-7 cells. Journal of Biological Chemistry 270 25244-25251.
98. Masamura S, Santner SJ, Heitjan DF & Santen RJ 1995 Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. Journal of Clinical Endocrinology and Metabolism 80 2918-2925.
99. Massarweh S, Shou J, Mohsin SK, Ge M, Wakeling AE, Osborne CK & Schiff R 2002 Inhibition of epidermal growth factor/HER2 receptor signaling using ZD1839 ('Iressa') restores tamoxifen sensitivity and delays resistance to estrogen deprivation in HER2-overexpressing breast tumors. Proceedings of the American Society of Clinical Oncology 21 (abstract 130).
100. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E & Auricchio F 1996 Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO Journal 15 1292-1300.
101. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF & Arteaga CL 2001 Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Research 61 8887-8895.
102. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P & Bhatnagar A 2003 Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. Journal of Clinical Oncology 21 2101-2109.
103. Mueller H, Kueng W, Schoumacher F, Herzer S & Eppenberger U 1995 Selective regulation of steroid receptor expression in MCF-7 breast cancer cells by a novel member of the heregulin family. Biochemical and Biophysical Research Communications 217 1271-1278.
104. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A & von Euler M 2000 Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. Journal of Clinical Oncology 18 3758-3767.
105. Nicholson RI, Staka C, Boyns F, Hutcheson IR & Gee JM 2004 Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocrine-Related Cancer 11 623-641.
106. Normanno N, Qi CF, Gullick WJ, Persico G, Yarden Y, Wen D, Plowman G, Kenney N, Johnson G, Kim N, Brandt R & Salomon DS 1993 Expression of amphiregulin, cripto-1 and heregulin-α in human breast cancer cell lines. International Journal of Oncology 2 903-911.
107. Normanno N, Ciardiello F, Brandt R & Salomon DS 1994 Epidermal growth factor-related peptides in the pathogenesis of human breast cancer. Breast Cancer Research and Treatment 29 11-27.
108. Normanno N, Campiglio M, De Luca A, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS & Menard S 2002 Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Annals of Oncology 13 65-72.
109. Normanno N, De Luca A, Bianco C, Maiello MR, Carriero MV, Rehman A, Wechselberger C, Arra C, Strizzi L, Sanicola M & Salomon DS 2004a Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells. Journal of Cellular Physiology 198 31-39.
110. Normanno N, Maiello MR, Mancino M & De Luca A 2004b Small molecule epidermal growth factor receptor tyrosine kinase inhibitors: an overview. Journal of Chemotherapy 16 (Suppl 4) 36-40.
111. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG & El-Ashry D 2001 Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Molecular Endocrinology 15 1344-1359.
112. Osborne CK & Schiff R 2005 Estrogen-receptor biology: continuing progress and therapeutic implications. Journal of Clinical Oncology 23 1616-1622.
113. Osborne CK, Coronado E, Allred DC, Wiebe V & DeGregorio M 1991 Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. Journal of the National Cancer Institute 83 1477-1482.
114. Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AE 1994 The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemotherapy and Pharmacology 34 89-95.
115. Osborne CK, Schiff R, Fuqua SA & Shou J 2001 Estrogen receptor: current understanding of its activation and modulation. Clinical Cancer Research 7 4338-4342s.
116. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R & Buzdar A 2002 Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. Journal of Clinical Oncology 20 3386-3395.
117. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM & Schiff R 2003 Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. Journal of the National Cancer Institute 95 353-361.
118. Osborne CK, Shou J, Massarweh S & Schiff R 2005 Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clinical Cancer Research 11 865-870s.
119. Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB & Davidson NE 1994 Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Research 54 2552-2555.
120. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ & Scanlan TS 1997 Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP-1 sites. Science 277 1508-1510.
121. Paridaens R, Therasse P, Dirix L, Beex L, Piccart M, Cameron D, Cufer T, Roozendaal K, Nooij M & Mattiacci MR 2004 First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group. Proceedings of the American Society of Clinical Oncology 23 (abstract 515).
122. Parl FF 2003 Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer Pharmacogenomics Journal 3 251-253.
123. Perey L, Paridaens R, Nolè F, Pagani O, Bonnefoi H, Aebi S, Dietrich D, Goldhirsch A & Thurlimann B 2004 Fulvestrant (FaslodexTM) as
124. Perez-Tenorio G & Stal O; Southeast Sweden Breast Cancer Group 2002 Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. British Journal of Cancer 86 540-545.
125. Pettersson K, Delaunay F & Gustafsson JA 2000 Estrogen receptor β acts as a dominant regulator of estrogen signalling. Oncogene 19 4970-4978.
126. Piccart M, Parker LM & Pritchard KI 2003 Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer. Annals of Oncology 14 1017-1025.
127. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX & Slamon DJ 1995 HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10 2435-2446.
128. Polychronis A, Sinnett HD, Hadjiminas D, Singhal H, Mansi JL, Shivapatham D, Shousha S, Jiang J, Peston D, Barrett N, Vigushin D, Morrison K, Beresford E, Ali S, Slade MJ & Coombes RC 2005 Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncology 6 383-391.
129. Ray P, Ghosh SK, Zhang DH & Ray A 1997 Repression of interleukin-6 gene expression by 17 beta-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-kappa B by the estrogen receptor. FEBS Letters 409 79-85.
130. Razandi M, Pedram A, Park ST & Levin ER 2003 Proximal events in signaling by plasma membrane estrogen receptors. Journal of Biology Chemistry 278 2701-2712.
131. Ring A & Dowsett M 2004 Mechanisms of tamoxifen resistance. Endocrine-Related Cancer 11 643-658.
132. Robertson JFR, Gutteridge E, Cheung KL, Owers R, Koehler M, Hamilton L, Gee J & Nicholson RI 2003a Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: results from a phase II study. Proceedings of the American Society for Clinical Oncology 22 7.
133. Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S et al. 2003b Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98 229-238.
134. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL & Wolffe AP 2000 DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nature Genetics 25 338-342.
135. Ropero S, Menendez JA, Vazquez-Martin A, Montero S, Cortes-Funes H & Colomer R 2004 Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma. Breast Cancer Research and Treatment 86 125-137.
136. Rountree MR, Bachman KE & Baylin SB 2000 DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nature Genetics 25 269-277.
137. Rudloff J, Boulay A, Zumstein-Mecker S, Evans DB, O'Reilly T, Lane HA 2004 The mTOR pathway in estrogen response: a potential for combining the rapamycin derivative RAD001 with the aromatase inhibitor Letrozole (Femara) in breast carcinoma. Proceedings of the American Association for Cancer Research 45 A5619.
138. Saeki T, Cristiano A, Lynch MJ, Brattain M, Kim N, Normanno N, Kenney N, Ciardiello F & Salomon DS 1991 Regulation by estrogen through the 5′-flanking region of the transforming growth factor alpha gene. Molecular Endocrinology 5 1955-1963.
139. Safe S 2001 Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitamins and Hormones 62 231-252.
140. Salomon DS, Brandt R, Ciardiello F & Normanno N 1995 Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology and Hematology 19 183-232.
141. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura S, Yue W & Berstein L 2003 Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention. Endocrine-Related Cancer 10 111-130.
142. Schiff R, Massarweh S, Shou J & Osborne CK 2003 Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clinical Cancer Research 9 447-454S.
143. Schiff R, Massarweh S, Shou J, Bharwani L, Mohsin SK & Osborne CK 2004 Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clinical Cancer Research 10 331-336S.
144. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA & Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 927-937.
145. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H & Schiff R 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. Journal of the National Cancer Institute 96 926-935.
146. Song RX, Santen RJ, Kumar R, Adam L, Jeng MH, Masamura S & Yue W 2002a Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells. Molecular and Cellular Endocrinology 193 29-42.
147. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R & Santen RJ 2002b Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and She pathway activation. Molecular Endocrinology 16 116-127.
148. Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R & Santen RJ 2004 The role of She and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. PNAS 101 2076-2081.
149. Speirs V, Malone C, Walton DS, Kerin MJ & Atkin SL 1999 Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Research 59 5421-5424.
150. Stal O, Borg A, Ferno M, Kallstrom AC, Malmstrom P & Nordenskjold B; South Sweden Breast Cancer Group. Southeast Sweden Breast Cancer Group 2000 ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Annals of Oncology 11 1545-1550.
151. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z & Flockhart DA 2003 Active tamoxifen metabolite plasma concentration after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Journal of the National Cancer Institute 95 1758-1764.
152. Stoica A, Saceda M, Fakhro A, Salomon HB, Fenster BD & Martin MB 1997 The role of transforming growth factor-beta in regulation of estrogen receptor expression in the MCF-7 breast cancer cell line. Endocrinology 138 1498-1505.
153. Stoica A, Saceda M, Fakhro A, Joyner M & Martin MB 2000a Role of insulin-like growth factor-I in regulating estrogen receptor-alpha gene expression. Journal of Cellular Biochemistry 76 605-614.
154. Stoica A, Saceda M, Doraiswamy VL, Coleman C & Martin MB 2000b Regulation of estrogen receptor-alpha gene expression by epidermal growth factor. Journal of Endocrinology 165 371-378.
155. Strasser-Weippl K & Goss E 2005 Advances in adjuvant hormonal therapy for postmenopausal women. Journal of Clinical Oncology 23 1751-1759.
156. Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV & Cheng JQ 2001 Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Research 61 5985-5991.
157. Tang CK, Perez C, Grunt T, Waibel C, Cho C & Lupu R 1996 Involvment of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Research 56 3350-3358.
158. Thurlimann BJ, Keshaviah A, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Smith I & Goldhirsch A 2005 BIG 1-98: randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer Proceedings of the American Society of Clinical Oncology 24 (abstract 511).
159. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW & McDonnell DP 1994 Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Molecular Endocrinology 8 21-30.
160. Valverius EM, Velu T, Shankar V, Ciardiello F, Kim N & Salomon DS 1990 Over-expression of the epidermal growth factor receptor in human breast cancer cells fails to induce an estrogen-independent phenotype. International Journal of Cancer 46 712-718.
161. Vergote I, Robertson JF, Kleeberg U, Burton G, Osborne CK & Mauriac L; Trial 0020 Investigators; Trial 0021 Investigators 2003 Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Research and Treatment 79 207-211.
162. Wegman P, Vainikka L, Stål O, Nordenskjöld B, Skoog L, Rutqvist LE & Wingren S 2005 Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Research 7 R284-290.
163. Weigel RJ & deConinck EC 1993 Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma. Cancer Research 53 3472-3474.
164. Wong CW, McNally C, Nickbarg E, Komm BS & Cheskis BJ 2002 Estrogen receptor-interacting protein that modulates its nongenimic activity-crosstalk with Src/Erk phosphorylation cascade. PNAS 99 14783-14788.
165. Wong ZW, Isaacs C, Harris L & Ellis MJ 2003 A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer. Breast Cancer Research and Treatment 82 S106.
166. Wright C, Nicholson S, Angus B, Sainsbury JR, Farndon J, Cairns J, Harris AL & Home CH 1992 Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. British Journal of Cancer 65 118-121.
167. Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, Herman JG & Davidson NE 2000 Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Research 60 6890-6894.
168. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG & Davidson NE 2001 Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Research 61 7025-7029.
169. Yao K, Lee ES, Bentrem DJ, England G, Schafer JI, O'Regan RM & Jordan VC 2000 Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clinical Cancer Research 6 2028-2036.
170. Yue W, Wang JP, Conaway MR, Li Y & Santen RJ 2003 Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways. Journal of Steroid Biochemistry and Molecular Biology 86 265-274.